<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01926457</url>
  </required_header>
  <id_info>
    <org_study_id>UCSD-GDM-RCT</org_study_id>
    <nct_id>NCT01926457</nct_id>
  </id_info>
  <brief_title>Treating Prediabetes in the First Trimester</brief_title>
  <official_title>Treating Prediabetes in the First Trimester: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Obstetricians and Gynecologists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Society for Maternal-Fetal Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to study a sample of women with prediabetes (diagnosed by Hemoglobin
      A1c (HbA1c) 5.7-6.4% or fasting plasma glucose (FPG) 92-125 mg/dL) in the first trimester of
      pregnancy, and patients will be randomized to first trimester or third trimester treatment;
      the first trimester group will receive intervention immediately upon diagnosis of prediabetes
      whereas the third trimester group will receive only routine prenatal care until 28 weeks at
      which time they will receive intervention.

      Intervention is defined as:

        -  diabetes education

        -  blood glucose monitoring

        -  medications as needed

        -  growth ultrasounds

        -  antenatal testing

      The primary outcome is umbilical cord C-Peptide &gt;90th percentile. Secondary outcomes include
      neonatal fat mass at delivery, infant weight-for-length at 12 months of age, maternal
      gestational weight gain, and biomarkers (chemicals) measured in the placenta and the baby's
      umbilical cord blood.

      The investigators hypothesize that women who undergo the above intervention in the first
      trimester will deliver significantly fewer neonates with umbilical cord C-Peptide &gt;90th
      percentile, and that the neonates will have lower fat mass, and weight-for-length at 12
      months. The investigators further hypothesize that a greater proportion of patients
      undergoing first trimester intervention will have appropriate maternal gestational weight
      gain as defined by the Institute of Medicine, and a greater proportion will return to
      prepregnancy weight within 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of the proposed research is to demonstrate that promoting a normoglycemic
      intrauterine milieu in women with prediabetes diagnosed in the first trimester of pregnancy
      with a Hemoglobin A1c (HbA1c) 5.7-6.4% or fasting plasma glucose (FPG) 92-125 mg/dL will
      decrease the accumulation of fetal white adipose tissue and development of infant/child
      obesity during the first year of life. This project is built upon the hypothesis that
      pregnant subjects with prediabetes randomized in the first trimester of pregnancy to strict
      glycemic control and pharmacotherapy as needed will have less fetal adiposity and adverse
      neonatal outcomes than those who receive the diagnosis of prediabetes but do not initiate
      care until the third trimester.

      In the proposed study, 240 women meeting the above criteria for prediabetes at ≤ 15w0d
      gestation will be randomized to either first trimester or third trimester treatment. Each
      group will have diabetes education, initiate blood glucose monitoring, begin pharmacotherapy
      as needed (per established protocol), undergo growth ultrasounds, and antenatal testing. The
      first trimester arm will receive the above interventions immediately upon diagnosis of
      prediabetes whereas the third trimester arm will receive only routine prenatal care until 28
      weeks at which time they will begin education and treatment. Both groups will be treated
      identically from 28 weeks until delivery.

      In the 2013 the National Institutes of Health (NIH) Gestational Diabetes (GDM) Consensus
      Conference, the panel was concerned about adopting criteria that would increase prevalence of
      GDM (i.e. first trimester treatment) without first demonstrating improved outcomes. The
      results of this proposed trial, will allow us to fill key research gaps; this is the first
      prospective trial to evaluate the International Associations of Diabetes in Pregnancy Study
      Groups (IADPSG) recommendations for screening and diagnosing prediabetes in the first
      trimester.

      Findings from this research will quantify the maternal and neonatal benefits and harms of
      treating women with prediabetes from early pregnancy. Additionally, the cohort of neonates
      that will result from this study can be followed into childhood to evaluate whether first
      trimester treatment has benefits beyond those anticipated at birth and may decrease the
      long-term incidence of obesity and diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor Enrollment
  </why_stopped>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Umbilical Cord C-Peptide &gt;90th percentile</measure>
    <time_frame>1 day (Collected at the time of delivery)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neonatal fat mass</measure>
    <time_frame>Within 48 hours of delivery</time_frame>
    <description>Neonatal fat mass will be measured using an anthropometric model using weight, length, and flank skinfold thickness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to the Institute of Medicine (IOM) guidelines for gestational weight gain</measure>
    <time_frame>Weight gain will be measured from immediately preconception until delivery</time_frame>
    <description>The IOM recommends that underweight women (BMI&lt;18.5kg/m2) gain 28-40lbs, normal women (BMI 18.5-24.9 kg/m2) gain 25-35lbs, overweight women (BMI 25.0-29.9 kg/m2) gain 15-25lbs and obese women (BMI≥30 kg/m2) gain 11-20 lbs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to prepregnancy weight</measure>
    <time_frame>After 1 year post delivery</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>birthweight</measure>
    <time_frame>At delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>birthweight percentile</measure>
    <time_frame>At delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Infant gender</measure>
    <time_frame>At delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Ponderal index</measure>
    <time_frame>At delivery</time_frame>
    <description>Weight/length^3</description>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal Intensive Care Unit (NICU) Admission</measure>
    <time_frame>Within 10 days after birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Infant weight-for-length</measure>
    <time_frame>6 months and 12 months after delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Need for pharmacotherapy to control hyperglycemia</measure>
    <time_frame>From 5 weeks gestation until time of delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Birth trauma</measure>
    <time_frame>At delivery</time_frame>
    <description>Shoulder dystocia, brachial plexus injury</description>
  </other_outcome>
  <other_outcome>
    <measure>Mode of delivery</measure>
    <time_frame>At delivery</time_frame>
    <description>Spontaneous delivery, operative vaginal delivery, cesarean delivery</description>
  </other_outcome>
  <other_outcome>
    <measure>Indication for delivery</measure>
    <time_frame>At delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total gestational weight gain</measure>
    <time_frame>From immediately preconception until delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Postpartum weight retention</measure>
    <time_frame>Within 1 year of delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Diagnosis of Preeclampsia</measure>
    <time_frame>From 20 weeks gestation until 6 weeks postpartum</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Prediabetes</condition>
  <condition>Gestational Diabetes</condition>
  <arm_group>
    <arm_group_label>First Trimester Treatment of Prediabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to first trimester treatment will receive the following intervention immediately initiated upon diagnosis of prediabetes at &lt;15 weeks 0 days gestation
diabetes education
blood glucose monitoring
medications as needed per California Diabetes and Pregnancy established protocol
growth ultrasounds
antenatal testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Third Trimester Treatment of Prediabetes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to third trimester treatment will receive the following intervention to be initiated at 28 weeks of gestation
diabetes education
blood glucose monitoring
medications as needed per California Diabetes and Pregnancy established protocol
growth ultrasounds
antenatal testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment of Prediabetes</intervention_name>
    <description>Standardized treatment of prediabetes per California Diabetes and Pregnancy Program &quot;Sweet Success&quot;
diabetes education
blood glucose monitoring
medications as needed per California Diabetes and Pregnancy established protocol
growth ultrasounds
antenatal testing</description>
    <arm_group_label>First Trimester Treatment of Prediabetes</arm_group_label>
    <arm_group_label>Third Trimester Treatment of Prediabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women age 18 and above

          -  Any ethnic background

          -  English- or Spanish-speaking

          -  Planned prenatal care/delivery at The University of California, San Diego's Hillcrest
             Hospital

          -  Singleton pregnancy

          -  Prediabetes diagnosed prior to 15w0d with HbA1c 5.7-6.4% or FPG 92-125 mg/dL

        Exclusion Criteria:

          -  Known Type 2 Diabetes (T2DM)

          -  T2DM diagnosed with first trimester screening

          -  Patients with known maternal/fetal indications for delivery &lt;36w0d

          -  Patients presenting for care after 15w0d
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hilary A Roeder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC San Diego Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gladys A Ramos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC San Diego Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas R Moore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC San Diego Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC San Diego Health System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.aaogf.org/</url>
    <description>The American Association of Obstetricians and Gynecologists Foundation</description>
  </link>
  <link>
    <url>https://www.smfm.org/about%20smfm%20foundation%20page.cfm?ht=s</url>
    <description>The Society For Maternal-Fetal Medicine Pregnancy Foundation</description>
  </link>
  <link>
    <url>http://repromed.ucsd.edu/</url>
    <description>UC San Diego Health System Department of Reproductive Medicine</description>
  </link>
  <reference>
    <citation>HAPO Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations with neonatal anthropometrics. Diabetes. 2009 Feb;58(2):453-9. doi: 10.2337/db08-1112. Epub 2008 Nov 14.</citation>
    <PMID>19011170</PMID>
  </reference>
  <reference>
    <citation>HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008 May 8;358(19):1991-2002. doi: 10.1056/NEJMoa0707943.</citation>
    <PMID>18463375</PMID>
  </reference>
  <reference>
    <citation>Catalano PM, Thomas A, Huston-Presley L, Amini SB. Increased fetal adiposity: a very sensitive marker of abnormal in utero development. Am J Obstet Gynecol. 2003 Dec;189(6):1698-704.</citation>
    <PMID>14710101</PMID>
  </reference>
  <reference>
    <citation>Kim SY, Sharma AJ, Callaghan WM. Gestational diabetes and childhood obesity: what is the link? Curr Opin Obstet Gynecol. 2012 Dec;24(6):376-81. doi: 10.1097/GCO.0b013e328359f0f4. Review.</citation>
    <PMID>23000698</PMID>
  </reference>
  <reference>
    <citation>Catalano PM, McIntyre HD, Cruickshank JK, McCance DR, Dyer AR, Metzger BE, Lowe LP, Trimble ER, Coustan DR, Hadden DR, Persson B, Hod M, Oats JJ; HAPO Study Cooperative Research Group. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. Diabetes Care. 2012 Apr;35(4):780-6. doi: 10.2337/dc11-1790. Epub 2012 Feb 22.</citation>
    <PMID>22357187</PMID>
  </reference>
  <reference>
    <citation>Hedderson MM, Gunderson EP, Ferrara A. Gestational weight gain and risk of gestational diabetes mellitus. Obstet Gynecol. 2010 Mar;115(3):597-604. doi: 10.1097/AOG.0b013e3181cfce4f. Erratum in: Obstet Gynecol. 2010 May;115(5):1092.</citation>
    <PMID>20177292</PMID>
  </reference>
  <reference>
    <citation>International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, Dyer AR, Leiva Ad, Hod M, Kitzmiler JL, Lowe LP, McIntyre HD, Oats JJ, Omori Y, Schmidt MI. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010 Mar;33(3):676-82. doi: 10.2337/dc09-1848. Review.</citation>
    <PMID>20190296</PMID>
  </reference>
  <reference>
    <citation>Catalano PM, Thomas AJ, Avallone DA, Amini SB. Anthropometric estimation of neonatal body composition. Am J Obstet Gynecol. 1995 Oct;173(4):1176-81.</citation>
    <PMID>7485315</PMID>
  </reference>
  <reference>
    <citation>Riskin-Mashiah S, Younes G, Damti A, Auslender R. First-trimester fasting hyperglycemia and adverse pregnancy outcomes. Diabetes Care. 2009 Sep;32(9):1639-43. doi: 10.2337/dc09-0688. Epub 2009 Jun 23.</citation>
    <PMID>19549728</PMID>
  </reference>
  <reference>
    <citation>Persson B, Heding LG, Lunell NO, Pschera H, Stangenberg M, Wager J. Fetal beta cell function in diabetic pregnancy. Amniotic fluid concentrations of proinsulin, insulin, and C-peptide during the last trimester of pregnancy. Am J Obstet Gynecol. 1982 Oct 15;144(4):455-9.</citation>
    <PMID>6751089</PMID>
  </reference>
  <reference>
    <citation>Lappas M, Andrikopoulos S, Permezel M. Hypoxanthine-xanthine oxidase down-regulates GLUT1 transcription via SIRT1 resulting in decreased glucose uptake in human placenta. J Endocrinol. 2012 Apr;213(1):49-57. doi: 10.1530/JOE-11-0355. Epub 2012 Jan 19.</citation>
    <PMID>22266962</PMID>
  </reference>
  <reference>
    <citation>Gillum MP, Kotas ME, Erion DM, Kursawe R, Chatterjee P, Nead KT, Muise ES, Hsiao JJ, Frederick DW, Yonemitsu S, Banks AS, Qiang L, Bhanot S, Olefsky JM, Sears DD, Caprio S, Shulman GI. SirT1 regulates adipose tissue inflammation. Diabetes. 2011 Dec;60(12):3235-45. doi: 10.2337/db11-0616.</citation>
    <PMID>22110092</PMID>
  </reference>
  <reference>
    <citation>Banks AS, Kon N, Knight C, Matsumoto M, Gutiérrez-Juárez R, Rossetti L, Gu W, Accili D. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab. 2008 Oct;8(4):333-41. doi: 10.1016/j.cmet.2008.08.014.</citation>
    <PMID>18840364</PMID>
  </reference>
  <reference>
    <citation>Astapova O, Leff T. Adiponectin and PPARγ: cooperative and interdependent actions of two key regulators of metabolism. Vitam Horm. 2012;90:143-62. doi: 10.1016/B978-0-12-398313-8.00006-3. Review.</citation>
    <PMID>23017715</PMID>
  </reference>
  <reference>
    <citation>Qiao L, Yoo HS, Madon A, Kinney B, Hay WW Jr, Shao J. Adiponectin enhances mouse fetal fat deposition. Diabetes. 2012 Dec;61(12):3199-207. doi: 10.2337/db12-0055. Epub 2012 Aug 7.</citation>
    <PMID>22872236</PMID>
  </reference>
  <reference>
    <citation>Luo ZC, Nuyt AM, Delvin E, Fraser WD, Julien P, Audibert F, Girard I, Shatenstein B, Deal C, Grenier E, Garofalo C, Levy E. Maternal and fetal leptin, adiponectin levels and associations with fetal insulin sensitivity. Obesity (Silver Spring). 2013 Jan;21(1):210-6. doi: 10.1002/oby.20250.</citation>
    <PMID>23505188</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2013</study_first_submitted>
  <study_first_submitted_qc>August 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2013</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Hilary Roeder, MD</investigator_full_name>
    <investigator_title>Physican, Clinical Instructor, Maternal-Fetal Medicine</investigator_title>
  </responsible_party>
  <keyword>First trimester treatment of prediabetes</keyword>
  <keyword>First trimester treatment of gestational diabetes</keyword>
  <keyword>Umbilical cord C-Peptide</keyword>
  <keyword>Neonatal fat mass</keyword>
  <keyword>Gestational weight gain</keyword>
  <keyword>Infant obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

